IN VITRO INVESTIGATION OF RADIOLABELED ENCAPSULATED EVEROLIMUS AND SALINOMYCIN
Project no. 109 · Status: Kapanmış · 2017
Summary
It is known that cervical and ovarian cancers are common gynecological cancers in women, and it is seen that especially these cancer types are very popular for drug diagnosis systems. There are many studies in the literature showing that polymer-based nanoparticles such as biocompatible and non-toxic Poly (lactic-co-glycolic acid) (PLGA) and silica nanoparticles are effective in transporting various molecules (such as ionophore group drugs, mTOR inhibitors) to targeted cancer cells. In the present study, it is aimed to develop radiolabeled drug delivery systems that can offer diagnosis opportunities for cervix and ovarian cancers. For this purpose, Everolimus (EVE), an mTOR inhibitor drug, was encapsulated with poly lactic-coglycolic acid (PLGA) and silica nanoparticles of Salinomycin (Sal), an ionophore group of drugs, were synthesized. Then, bioaffinity of radiolabeled compounds (99mTc-EVE, 99mTc-EVE-PLGA, 99mTc-Sal, 99mTc-Sal-SN) were evaluated on cervix and ovarian cancers by using in vitro methods. In experimental studies, radiolabeling efficiencies of 99mTc-EVE-PLGA and 99mTc- Sal-SN compounds were determined as % 98.68 ± 2.52 ve % 48.66 ± 5.24, respectively. Within the scope of in vitro studies, cytotoxicity and incorporation studies were carried out on HeLa, SKOV3 and MDAH-2774 cell lines. It is thought that the data obtained in current project will contribute to the development of new agents for radiolabeled polymeric and silica drug delivery systems.